

# **Global Phosphate Binder (Hyperphosphatemia) Market: Industry Analysis & Outlook**

---

**(2019-2023)**

**May 2019**



# Executive Summary

Phosphate binder also referred as phosphorus binder, is a medication prescribed to reduce the absorption of dietary phosphate and to control the amount of phosphorus in the blood. They are frequently used by people with chronic kidney failure, who are not able to excrete phosphate and causing a high level of phosphate level in the body. Phosphate binders bind phosphate and are then excreted from the body.

Phosphate binders such as aluminum-based antacids, magnesium-based antacids, calcium carbonate, calcium acetate, sevelamer, and lanthanum are essential for patients whose phosphorus levels stay high despite dietary restrictions. Controlling phosphate level is important as it is associated with bone pathology and accompanied with elevated calcium level by the parathyroid hormone.


The global phosphate binder market is driven by an increasing aging population as well as the rising prevalence of chronic kidney diseases. The drugs, namely Velphoro, Auryxia, PhosLo, and Renegal are expected to show high growth prospects in the coming years. Since a large part of the population suffers from kidney diseases, the chances of developing end-stage renal failure have increased to a large extent, thereby propelling the growth of the market during the forecasted period.

With the advancements in the healthcare infrastructure in the U.S., the phosphate binder medication growth is estimated to continue and thereby, making this region a potential opportunity for manufacturers. The number of treated population is also rising owing to increase in awareness regarding treatment.

The report “Global Phosphate Binder Market: Industry Analysis & Outlook (2019-2023)” by Konzept Analytics provides extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the United States, Europe, and Japan regions along with the global market. The report profiles the key players of the market including AMAG Pharmaceuticals, Inc., Vifor Pharma Ltd., Sanofi S.A., and Akebia Therapeutics Inc.


# Rising aging population and increasing health care expenditure supported the growth of phosphate binder market.

## Global Phosphate Binders Drugs in Development (2018)




- A total of ... drugs were in Phase 3 development level for high phosphate levels in chronic kidney disease patients in the year 2018. ...drugs are under pre-clinical trials for the treatment of hyperphosphataemia.
- Calcium acetates accounted for ...% prescription share, maintaining the stable share in the market in 2018. Auryxia accounted for ..% share in May-2018, increasing from ...% share in Dec-2017.
- The number of prescriptions were recorded at ..thousand in April 2018 as compared to ...thousand in Mar-2018. Total tablet count also increased from ...million to ...million during Mar-April 2018 period.

## Global Phosphate Binder Prescription Market Share (Dec 2017- May 2018)




## Auryxia Prescription and Tablets Count (Jan 2017-Apr 2018)






# Increasing incidences of ESRD and high unmet medical needs will drive the phosphate binder market globally.

**The U.S. Dialysis Patients on Phosphate Binder Forecast (2018-2023)**




- Phosphate binder treated dialysis population in the U.S. reached ...thousand in 2018 and is estimated to increase to ....thousand in 2023, growing at a CAGR of ...% for the period spanning 2018-2023.
- Auryxia revenue was recorded at US\$...million in 2018 and is estimated to increase to US\$...million in 2023. Auryxia drug revenue is predicted to grow at a CAGR of ...% for the period spanning 2018-2023.
- Velpora revenue in Europe is expected to reach US\$...million in 2023, increasing from US\$...million in 2018, recording growth at a CAGR of ....% for the period spanning 2018-2023.

**The U.S. Auryxia Revenue and Penetration Forecast (2018-2023)**



**Europe Velporo Revenue Forecast (2018-2023)**



# Disclaimer

This is a licensed product of Koncept Analytics. You cannot reproduce, publish, distribute, publicly display, sell or create other works from this report or use them in any way for commercial purpose without our prior permission. Further, you cannot copy this material, by any means (including electronic copies), for distribution to others unless you have purchased the corporate license of this report.

We believe the sources are reliable, but Koncept Analytics does not warranty the accuracy or completeness of the data. The data presented in the report is updated at the publication date but is subject to change at subsequent releases. All possible efforts have been made to ensure accuracy of data. However, investors should not completely rely on the information given in this report and must make decisions based on their own investment strategy, risk management and capital adequacy.

**Koncept Analytics**  
**CS-36, First Floor, Ansal Plaza**  
**Vaishali, Ghaziabad,**  
**U.P. – 201010**  
**T: +91-120-4130959**  
**M: +91-9811715635**  
**vikas@konceptanalytics.com**

**[www.konceptanalytics.com](http://www.konceptanalytics.com)**